GENERIC NAME formulation (Brand name®▼) for some indication

# The Pan Mersey Area Prescribing Committee recommends the prescribing of GENERIC NAME formulation (Brand name®▼), for some indication in accordance with NICE TAXXX.

## GREEN

Do not repeat statement in box above. Only add a similar statement if extra information included as clarification. If it is a new drug, it may be useful to add some information about licensed use.

Define which specialists can prescribe. Prescribing should be retained by the specialist.

NICE technology appraisal (TA) xxx recommends GENERIC NAME formulation (Brand name®▼) as an option for treating some indication only if:

* criteria 1
* criteria 2 etc

Reference NICE guidance and any relevant local guidance also available on the same subject matter (hyperlink or ask for hyperlink to be inserted in final version). When quoting NICE guidance refer to the TA number and the date published.

Costing information - Top-line information e.g. changes in drug cost per 100,000 population, change in activity cost per 100,000 population.

GENERIC NAME formulation (Brand name®▼) for some indication

|  |
| --- |
| Effectiveness Evidence summary and mechanism of action. |
| Safety Include contraindications, significant warnings and cautions, and frequent side-effects.  If there are too many then generalise and refer to SPC. |
| Cost Calculate one year cost i.e. 365 days, unless not appropriate. Source cost information using the latest edition of the electronic Drug Tariff as a first choice. Always quote costs without adding V.A.T.  Expected patient numbers per 100,000 population.  Costing information - Top-line information, e.g., change in drug cost per 100,000 population, change in activity cost per 100,000 population. |
| Patient factors Specify particular patient groups which may require dose adjustment or monitoring. |

GENERIC NAME formulation (Brand name®▼) for some indication

|  |
| --- |
| Effectiveness Evidence summary and mechanism of action. |
| Safety Include contraindications, significant warnings and cautions, and frequent side-effects.  If there are too many then generalise and refer to SPC. |
| Cost Calculate one year cost i.e. 365 days, unless not appropriate. Source cost information using the latest edition of the electronic Drug Tariff as a first choice. Always quote costs without adding V.A.T.  Expected patient numbers per 100,000 population.  Costing information - Top-line information, e.g., change in drug cost per 100,000 population, change in activity cost per 100,000 population. |
| Patient factors Specify particular patient groups which may require dose adjustment or monitoring. |

GENERIC NAME formulation (Brand name®▼) for some indication

|  |
| --- |
| Effectiveness Evidence summary and mechanism of action. |
| Safety Include contraindications, significant warnings and cautions, and frequent side-effects.  If there are too many then generalise and refer to SPC. |
| Cost Calculate one year cost i.e. 365 days, unless not appropriate. Source cost information using the latest edition of the electronic Drug Tariff as a first choice. Always quote costs without adding V.A.T.  Expected patient numbers per 100,000 population.  Costing information - Top-line information, e.g., change in drug cost per 100,000 population, change in activity cost per 100,000 population. |
| Patient factors Specify particular patient groups which may require dose adjustment or monitoring. |

GENERIC NAME formulation (Brand name®▼) for some indication

|  |
| --- |
| Effectiveness Evidence summary and mechanism of action. |
| Safety Include contraindications, significant warnings and cautions, and frequent side-effects.  If there are too many then generalise and refer to SPC. |
| Cost Calculate one year cost i.e. 365 days, unless not appropriate. Source cost information using the latest edition of the electronic Drug Tariff as a first choice. Always quote costs without adding V.A.T.  Expected patient numbers per 100,000 population.  Costing information - Top-line information, e.g., change in drug cost per 100,000 population, change in activity cost per 100,000 population. |
| Patient factors Specify particular patient groups which may require dose adjustment or monitoring. |

### Prescribing information

Dose regimen and monitoring advice.

### Implementation notes

Arrangements for prescribing and monitoring.

### References

1. Reference 1 with hyperlink
2. Reference 2 with hyperlink